课题基金 / 基金详情

CARDIOVASCULAR ROLE OF SYMPATHETIC K+ CHANNEL GENES

CARDIOVASCULAR ROLE OF SYMPATHETIC K+ CHANNEL GENES
交感 K 通道基因的心血管作用
批准号:
6637501
负责人:
PETER R BRINK
金额:
$27.72万
依托单位国家:
美国
项目类别:
财政年份:
2000
资助国家:
美国
项目状态:
已结题
起止时间:
2000-03-01 至 2004-08-31

项目摘要

项目成果

PETER R BRINK的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Sympathetic neuronal activity regulates such cardiovascular variables as heart rate, arterial blood pressure and myocardial contractility. The excitability of sympathetic neurons is determined in large part by a conductance known as the M-current. These investigators have recently determined that the M-current is encoded by the KCNQ2 and KCNQ3 genes. Increased understanding of these genes is a prerequisite to further investigation of 1) how the M-current is regulated during sympathetic activity, 2) the developmental control of this current and 3) the targeting of the M-current, and the pathways involved in its regulation, for pharmacological interventions in cardiovascular pathologies. The overall goal of the present application is to understand at a molecular level the subunit interactions that generate the constituent channels of the M-current. The projects outlined in Specific Aim 1 use knock-out and gain-of-function experiments to confirm our hypothesis that the M-current of sympathetic neurons is encoded by KCNQ2 and KCNQ3. Specific Aim 2 would test the hypothesis that the formation of the M-current involves protein interaction between the KCNQ2 and KCNQ3 subunits. Specific Aim 3 would test the corollary that protein interaction between the subunits facilitates the movement of subunit proteins from the endoplasmic reticulum to the cell membrane. Specific Aim 4 would test the hypothesis that specific splice variants of the KCNQ2 and KCNQ3 genes encode the M-channel of sympathetic neurons.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
SiRNA therapeutics: Gap junction delivery in vitro and in vivo
SiRNA therapeutics: Gap junction delivery in vitro and in vivo
SiRNA therapeutics: Gap junction delivery in vitro and in vivo
SiRNA therapeutics: Gap junction delivery in vitro and in vivo
海外基金